← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Histrelin

FDA approved · Rx

GnRH receptor agonist

Also known as: Supprelin LA, Vantas, Supprelin La, Histrelina, Histreline, Histrelinum, ORF 17070, RWJ 17070, ORF-17070, RWJ-17070

Evidence score
89/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 15 registered studies on ClinicalTrials.gov, most advanced Phase 3
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Histrelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH), delivered as a long-acting subdermal implant. With continuous exposure it is thought to overstimulate and then desensitize GnRH receptors in the pituitary, lowering release of LH and FSH and in turn reducing sex hormone production.

What the evidence shows

Automatic summaryHuman trials

Histrelin is FDA-approved as Supprelin LA for central precocious puberty in children, and the Vantas implant was previously approved for palliative treatment of advanced prostate cancer. Its effects are supported by registered human trials up to Phase 3 and over a hundred published papers, while uses outside approved indications are not established.

Key facts

Molecular formula
C66H86N18O12
Molecular weight
1323.5 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

15registered studies
Phase 3most advanced phase
7completed (sample)
2recruiting (sample)

Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Phase 3CompletedNCT00779103

Markers of Pubertal Suppression During Therapy for Precocious Puberty

TerminatedNCT02006680

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Phase 3Active Not RecruitingNCT04787744

Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

Phase 3CompletedNCT01394263

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

125papers referencing Histrelin

Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.

Mol Pharm2015

Treatment and outcomes of precocious puberty: an update.

J Clin Endocrinol Metab2013

Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.

J Clin Endocrinol Metab2001

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Pharmacotherapy2008

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.